Sera Prognostics to Report Third Quarter Results
The Salt Lake City-based company is scheduled to release its fiscal financial results on November 4, 2026.
Updated on Oct. 21, 2026 in Economic Indicators
Live Poll
Do you trust quarterly corporate earnings reports as a reliable indicator of a company's long-term health?
Sera Prognostics, headquartered in Salt Lake City, will report its third quarter fiscal year 2026 financial results on November 4, 2026. Management will host a conference call and live webcast at 5:00 p.m. Eastern Time to discuss the results.
Why it matters
The company produces the PreTRM test, which measures blood proteins to help predict the risk of preterm birth. Addressing prematurity is a significant public health challenge, as the United States received a D+ grade in the 2025 March of Dimes Report Card.
The PreTRM test is conducted between weeks 18 and 20 of pregnancy to identify risks for births occurring before 37 weeks gestation. Healthcare costs for complications related to prematurity were estimated at $25 billion in 2016.
The players
Sera Prognostics
This Salt Lake City-based company specializes in identifying biological markers to predict pregnancy complications.
The details
Sera Prognostics will host a live audio webcast of the event on its website. Interested parties may also join the conference call by dialing (800) 836-8184 for domestic callers or (646) 357-8785 for international participants.
Timeline
Annual healthcare costs for prematurity were estimated at $25 billion in 2016.
The United States received a D+ grade for preterm birth rates in 2025.
Sera Prognostics will report its third quarter results on November 4, 2026.
The conference call is scheduled for November 4, 2026, at 5:00 p.m. ET.
Macro View
This financial update occurs as the healthcare sector continues to address the systemic challenges highlighted by the 2025 March of Dimes Report Card. The broader economic context remains focused on reducing the high costs associated with maternal and neonatal complications.
Investors and stakeholders should prepare for the upcoming results by monitoring the company's operational performance regarding the PreTRM test. The broader focus remains on the financial impact of preterm birth risks on the healthcare system.
The takeaway
Advancements in prenatal testing represent a key area for managing healthcare costs associated with preterm births. Stakeholders look to financial disclosures for insights into the adoption and economic impact of these diagnostic technologies.
What happens next
Sera Prognostics will host a conference call and live webcast on November 4, 2026, at 5:00 p.m. Eastern Time.
Further reading
For broader trends in local industry performance, visit Economic Indicators.
More information
To join the session, visit the conference call and webcast registration.
Live Poll
Do you trust quarterly corporate earnings reports as a reliable indicator of a company's long-term health?
